HDR interventional radiotherapy (brachytherapy) in the treatment of primary and recurrent head and neck malignancies

Maria Antonietta Gambacorta, Jacopo Galli, Gaetano Paludetti, Vincenzo Valentini, Francesco Bussu, Luca Tagliaferri, Claudio Parrilla, Davide Rizzo, Valentina Lancellotta, Carla Fonnesu, Caterina Kihlgren, György Kovács

Research output: Contribution to journalArticle

9 Citations (Scopus)


BACKGROUND: Interventional radiotherapy (brachytherapy; IRT) reemerged in the last decades as a potentially useful tool in head and neck oncology after a set of clear technical improvements were developed. METHODS: Sixty-one high dose ratio (HDR) IRT treatments were recommended and performed on 58 patients. We classified the cases into four relatively homogeneous groups based on the clinical needs that led to the recommended IRT. Also, we separately evaluated primary and recurrent cases. RESULTS: Disease-specific survival was significantly different among the four treatment groups. The group with the best prognosis was the cohort treated locally by exclusive interstitial IRT for resectable midface malignancies (2-year relapse-free survival = 82%, disease-specific survival = 89%). CONCLUSION: HDR IRT is a valuable tool in well-defined clinical situations and, in particular, in recurrences. In midface malignancies, it could become the preferred primary treatment.
Original languageEnglish
Pages (from-to)1667-1675
Number of pages9
JournalHEAD & NECK
Publication statusPublished - 2019


  • HDR
  • brachytherapy
  • head and neck cancer
  • interventional radiotherapy
  • nose vestibule


Dive into the research topics of 'HDR interventional radiotherapy (brachytherapy) in the treatment of primary and recurrent head and neck malignancies'. Together they form a unique fingerprint.

Cite this